1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1b study of sotorasib, a specific and irreversible KRAS(G12C) inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)
    Meeting Abstract

    Hong, D. S.; Yaeger, R.; Kuboki, Y.; Masuishi, T.; Barve, M. A.; Falchook, G. S.; Govindan, R.; Sohal, D.; Kasi, P. M.; Burns, T. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers
    Meeting Abstract

    Hong, D. S.; Jalal, S. I.; Elimova, E.; Ajani, J. A.; Blum Murphy, M. A.; Cervantes, A.; Jeffry Evans, T. R.; Park, H.; Lin, Q.; Noto, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of neuroendocrine neoplasms treated with immune checkpoint inhibitors: A single-institution experience
    Meeting Abstract

    Hauser, H.; Le, T.; Chou, J. F.; Heffernan, O.; DeMore, A.; Gonen, S.; Capanu, M.; Reidy, D. L.; Raj, N. P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for IDH1-mutated cholangiocarcinoma (CCA) in the ClarIDHy study
    Meeting Abstract

    Chamberlain, C. X.; Hua, Z. W.; Gliser, C.; Pandya, S. S.; Zhu, A. X.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Pivotal phase III COMPOSE trial will compare (177)Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors
    Meeting Abstract

    Halfdanarson, T. R.; Reidy, D. L.; Vijayvergia, N.; Halperin, D. M.; Goldstein, G.; Kong, G.; Michael, M.; Leyden, S.; Grozinsky-Glasberg, S.; Sorbye, H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
    Meeting Abstract

    Cohen, D. J.; Tabernero, J.; Van Cutsem, E.; Janjigian, Y. Y.; Bang, Y. J.; Qin, S.; Wainberg, Z. A.; Wang, A.; Hawk, N. N.; Shih, C. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes
    Meeting Abstract

    Gu, L.; Paras, M.; Rao, D.; Rotemberg, V.; Capanu, M.; Chou, J. F.; Sigel, C. S.; Busam, K. J.; Boyce, L.; Gordon, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Yarmohammadi, H.; Reiss, K. A.; Chou, J. F.; Capanu, M.; Do, R. K. G.; Khalil, D.; El Dika, I. H.; Ferrer, C. S.; Heffernan, O.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
    Meeting Abstract

    Harding, J. J.; Hofheinz, R. D.; Elez, E.; Kuboki, Y.; Rasco, D. W.; Cecchini, M.; Shen, L.; Dowling, E.; Archuadze, S.; de Pereira, B. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
    Meeting Abstract

    Abou-Alfa, G. K.; Chan, S. L.; Kudo, M.; Lau, G.; Kelley, R. K.; Furuse, J.; Sukeepaisarnjaroen, W.; Kang, Y. K.; Dao, T. V.; De Toni, E. N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save